Top

Published in:

01-09-2012 | Co-infections (C Benson, Section Editor)

New Insights in the Prevention, Diagnosis, and Treatment of Cryptococcal Meningitis

Authors: Arthur Jackson, Charles van der Horst

Published in: Current HIV/AIDS Reports | Issue 3/2012

Abstract

Cryptococcal meningitis (CM) remains a major cause of morbidity and mortality among immunocompromised patients, especially in areas of high HIV prevalence, although it can also cause disease in the apparently immunocompetent. Improving the management of HIV-associated CM is important to ensure that patients can survive to benefit from increasing access to ART. In this review we focus on recent advances in prevention, diagnosis, and treatment of CM.

Okongo M, Morgan D, Mayanja B, Ross A, Whitworth J. Causes of death in a rural, population-based human immunodeficiency virus type 1 (HIV-1) natural history cohort in Uganda. Int J Epidemiol. 1998;27(4):698–702. Epub 1998/10/03.PubMedCrossRef

French N, Gray K, Watera C, Nakiyingi J, Lugada E, Moore M, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS. 2002;16(7):1031–8.PubMedCrossRef

• Park B, Wannemuehler K, Marston B, Govender N, Pappas P, Chiller T. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23(4):525–30. This article highlights the devastating effect of this underappreciated disease in resource-limited areas. PubMedCrossRef

Kiertiburanakul S, Watcharatipagorn S, Chongtrakool P, Santanirand P. Epidemiology of bloodstream infections and predictive factors of mortality among HIV-infected adult patients in Thailand in the era of highly active antiretroviral therapy. Jpn J Infect Dis. 2012;65(1):28–32. Epub 2012/01/26.PubMed

Scarborough M, Gordon SB, Whitty CJ, French N, Njalale Y, Chitani A, et al. Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa. N Engl J Med. 2007;357(24):2441–50.PubMedCrossRef

Ellis DH, Pfeiffer TJ. Ecology, life cycle, and infectious propagule of Cryptococcus neoformans. Lancet. 1990;336(8720):923–5.PubMedCrossRef

Bartlett KH, Cheng PY, Duncan C, Galanis E, Hoang L, Kidd S, et al. A decade of experience: Cryptococcus gattii in British Columbia. Mycopathologia. 2012;173(5–6):311–9

Harris JR, Lockhart SR, Debess E, Marsden-Haug N, Goldoft M, Wohrle R, et al. Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin Infect Dis. 2011;53(12):1188–95.PubMedCrossRef

Patel M, Beckerman KP, Reznik S, Madan RP, Goldman DL. Transplacental transmission of Cryptococcus neoformans to an HIV-exposed premature neonate. J Perinatol. 2012;32(3):235–7.PubMedCrossRef

10.

Baddley JW, Schain DC, Gupte AA, Lodhi SA, Kayler LK, Frade JP, et al. Transmission of Cryptococcus neoformans by Organ Transplantation. Clin Infect Dis. 2011;52(4):e94–8.PubMedCrossRef

11.

Sun HY, Alexander BD, Lortholary O, Dromer F, Forrest GN, Lyon GM, et al. Unrecognized pretransplant and donor-derived cryptococcal disease in organ transplant recipients. Clin Infect Dis. 2010;51(9):1062–9.PubMedCrossRef

12.

Goldman DL, Khine H, Abadi J, Lindenberg DJ, Pirofski L, Niang R, et al. Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics. 2001;107(5):E66.PubMedCrossRef

13.

Davis J, Zheng WY, Glatman-Freedman A, Ng JA, Pagcatipunan MR, Lessin H, et al. Serologic evidence for regional differences in pediatric cryptococcal infection. Pediatr Infect Dis J. 2007;26(6):549–51.PubMedCrossRef

14.

van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med. 1997;337(1):15–21.PubMedCrossRef

15.

Pappas PG, Perfect JR, Cloud GA, Larsen RA, Pankey GA, Lancaster DJ, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis. 2001;33(5):690–9.PubMedCrossRef

16.

Shih CC, Chen YC, Chang SC, Luh KT, Hsieh WC. Cryptococcal meningitis in non-HIV-infected patients. QJM. 2000;93(4):245–51.PubMedCrossRef

17.

Blevins LB, Fenn J, Segal H, Newcomb-Gayman P, Carroll KC. False-positive cryptococcal antigen latex agglutination caused by disinfectants and soaps. J Clin Microbiol. 1995;33(6):1674–5.PubMed

18.

Wilson DA, Sholtis M, Parshall S, Hall GS, Procop GW. False-positive cryptococcal antigen test associated with use of BBL Port-a-Cul transport vials. J Clin Microbiol. 2011;49(2):702–3.PubMedCrossRef

19.

• Lindsley MD, Mekha N, Baggett HC, Surinthong Y, Autthateinchai R, Sawatwong P, et al. Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin Infect Dis. 2011;53(4):321–5. A study that validates the use of a newer, simpler, cheaper test for the diagnosis of CM. PubMedCrossRef

20.

Jarvis JN, Percival A, Bauman S, Pelfrey J, Meintjes G, Williams GN, et al. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis. 2011;53(10):1019–23.PubMedCrossRef

21.

Saha DC, Xess I, Biswas A, Bhowmik DM, Padma MV. Detection of Cryptococcus by conventional, serological and molecular methods. J Med Microbiol. 2009;58(Pt 8):1098–105.PubMedCrossRef

22.

Jurado R, Walker H. In: Walker H, Hall W, Hurst J, editors. Cerebrospinal fluid. 3rd ed. Butterworths; 1990.

23.

Yan Y, He Y, Maier T, Quinn C, Shi G, Li H, et al. Improved identification of yeast species directly from positive blood culture media by combining Sepsityper specimen processing and Microflex analysis with the matrix-assisted laser desorption ionization Biotyper system. J Clin Microbiol. 2011;49(7):2528–32.PubMedCrossRef

24.

Pinto A, Halliday C, Zahra M, van Hal S, Olma T, Maszewska K, et al. Matrix-assisted laser desorption ionization-time of flight mass spectrometry identification of yeasts is contingent on robust reference spectra. PLoS One. 2011;6(10):e25712.PubMedCrossRef

25.

Qishui O, Ling J, Ni L, Bin Y, Wen L. Comparison of real-time florescence quantitative PCR measurements of VAD1 mRNA with three conventional methods in diagnosis and follow-up treatment of Cryptococcus neoformans infection. Mycoses. 2011.

26.

Anekthananon T, Manosuthi W, Chetchotisakd P, Kiertiburanakul S, Supparatpinyo K, Ratanasuwan W, et al. Predictors of poor clinical outcome of cryptococcal meningitis in HIV-infected patients. Int J STD AIDS. 2011;22(11):665–70.PubMedCrossRef

27.

Brouwer A, Rajanuwong A, Chierakul W, Griffin G, Larsen R, White N, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet. 2004;363(9423):1764–7.PubMedCrossRef

28.

Graybill JR, Sobel J, Saag M, van Der Horst C, Powderly W, Cloud G, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis. 2000;30(1):47–54.PubMedCrossRef

29.

•• Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(3):291–322. Updated guidelines from IDSA on management of cryptococcosis, including CM. PubMedCrossRef

30.

• WHO. Rapid advice: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. 2011. Updated guidelines with practical advice on aspects of management of cryptococcal disease.

31.

Maher D, Mwandumba H. Cryptococcal meningitis in Lilongwe and Blantyre, Malawi. J Infect. 1994;28(1):59–64.PubMedCrossRef

32.

• Bicanic T, Muzoora C, Brouwer A, Meintjes G, Longley N, Taseera K, et al. Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis. 2009;49(5):702–9. This article validates early fungicidal activity (EFA) as a useful tool for assessing efficacy of anticryptococcal regimens. PubMedCrossRef

33.

Robinson PA, Bauer M, Leal MA, Evans SG, Holtom PD, Diamond DA, et al. Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin Infect Dis. 1999;28(1):82–92.PubMedCrossRef

34.

Hamill RJ, Sobel JD, El-Sadr W, Johnson PC, Graybill JR, Javaly K, et al. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. Clin Infect Dis. 2010;51(2):225–32.PubMedCrossRef

35.

• Nussbaum J, Jackson A, Namarika D, Phulusa J, Kenala J, Kanyemba C, et al. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis. 2010;50(3):338–44. This article shows the most effective oral regimen for CM to date, with EFA of fluconazole 1200 mg/day plus 5FC approaching that of AmB alone. It lends weight to the call for 5FC to be made available in resource-limited settings. PubMedCrossRef

36.

Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med. 2007;4(2):e21.PubMedCrossRef

37.

Bicanic T, Meintjes G, Wood R, Hayes M, Rebe K, Bekker L, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis. 2007;45(1):76–80.PubMedCrossRef

38.

Mwaba P, Mwansa J, Chintu C, Pobee J, Scarborough M, Portsmouth S, et al. Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad Med J. 2001;77(914):769–73.PubMedCrossRef

39.

Bicanic T, Harrison T, Niepieklo A, Dyakopu N, Meintjes G. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis. 2006;43(8):1069–73.PubMedCrossRef

40.

Mdodo R, Moser SA, Jaoko W, Baddley J, Pappas P, Kempf MC, et al. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates from AIDS patients in Kenya. Mycoses. 2011;54(5):e438–42.PubMedCrossRef

41.

Govender NP, Patel J, van Wyk M, Chiller TM, Lockhart SR, Group for Enteric RaMDSiSA. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates obtained through population-based surveillance in South Africa in 2002–2003 and 2007–2008. Antimicrob Agents Chemother. 2011;55(6):2606–11.PubMedCrossRef

42.

Longley N, Muzoora C, Taseera K, Mwesigye J, Rwebembera J, Chakera A, et al. Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis. 2008;47(12):1556–61.PubMedCrossRef

43.

Muzoora CK, Kabanda T, Ortu G, Ssentamu J, Hearn P, Mwesigye J, et al. Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis. J Infect. 2012;64(1):76–81.PubMedCrossRef

44.

• Jackson A, Phulusa J, Namarika D, Chikasema M, Kanyemba C, Nussbaum J, et al., editors. A randomized controlled trial studying the effect of oral flucytosine on short course amphotericin B plus fluconazole for the treatment of Cryptococcal meningitis in Malawi—a role for triple therapy? Abstract 1506. Infectious Diseases Society of America 48th Annual Meeting; 2010; Vancouver, Canada. This study demonstrates the safe and effective use of shortened-course AmB for CM, and contributes to the evidence supporting the use of 5FC in developing world settings.

45.

• Pappas P, Chetchotisakd P, Larsen R, Manosuthi W, Morris M, Anekthananon T, et al. A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis. 2009;48(12):1775–83. This study suggests improved efficacy in the treatment of CM when using 14 days of AmB with fluconazole 800 mg compared to AmB alone. PubMedCrossRef

46.

Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, Gallis H, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med. 1979;301(3):126–31.PubMedCrossRef

47.

Dismukes WE, Cloud G, Gallis HA, Kerkering TM, Medoff G, Craven PC, et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med. 1987;317(6):334–41.PubMedCrossRef

48.

Apseloff G, Hilligoss DM, Gardner MJ, Henry EB, Inskeep PB, Gerber N, et al. Induction of fluconazole metabolism by rifampin: in vivo study in humans. J Clin Pharmacol. 1991;31(4):358–61.PubMed

49.

Bozzette SA, Larsen RA, Chiu J, Leal MA, Jacobsen J, Rothman P, et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med. 1991;324(9):580–4.PubMedCrossRef

50.

Powderly WG, Saag MS, Cloud GA, Robinson P, Meyer RD, Jacobson JM, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med. 1992;326(12):793–8.PubMedCrossRef

51.

Saag M, Cloud G, Graybill J, Sobel J, Tuazon C, Johnson P, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis. 1999;28(2):291–6.PubMedCrossRef

52.

Vibhagool A, Sungkanuparph S, Mootsikapun P, Chetchotisakd P, Tansuphaswaswadikul S, Bowonwatanuwong C, et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin Infect Dis. 2003;36(10):1329–31.PubMedCrossRef

53.

Aberg JA, Price RW, Heeren DM, Bredt B. A pilot study of the discontinuation of antifungal therapy for disseminated cryptococcal disease in patients with acquired immunodeficiency syndrome, following immunologic response to antiretroviral therapy. J Infect Dis. 2002;185(8):1179–82.PubMedCrossRef

54.

12Brouwer A, Siddiqui A, Kester M, Sigaloff K, Rajanuwong A, Wannapasni S, et al. Immune dysfunction in HIV-seronegative, Cryptococcus gattii meningitis. J Infect. 2007;54(3):e165–8.PubMedCrossRef

55.

Netea MG, Brouwer AE, Hoogendoorn EH, Van der Meer JW, Koolen M, Verweij PE, et al. Two patients with cryptococcal meningitis and idiopathic CD4 lymphopenia: defective cytokine production and reversal by recombinant interferon- gamma therapy. Clin Infect Dis. 2004;39(9):e83–7.PubMedCrossRef

56.

• Jarvis JN, Meintjes G, Rebe K, Williams GN, Bicanic T, Williams A, et al. Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS. 2012;26(9):1105–1113. This study using a novel adjunct demonstrates a regimen with the highest recorded EFA.

57.

58.

Perfect JR, Cox GM, Dodge RK, Schell WA. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother. 1996;40(8):1910–3.PubMed

59.

Pfaller MA, Zhang J, Messer SA, Brandt ME, Hajjeh RA, Jessup CJ, et al. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother. 1999;43(1):169–71.PubMedCrossRef

60.

Barchiesi F, Spreghini E, Schimizzi AM, Maracci M, Giannini D, Carle F, et al. Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection. Antimicrob Agents Chemother. 2004;48(9):3312–6.PubMedCrossRef

61.

Serena C, Pastor FJ, Marine M, Rodriguez MM, Guarro J. Efficacy of voriconazole in a murine model of cryptococcal central nervous system infection. J Antimicrob Chemother. 2007;60(1):162–5.PubMedCrossRef

62.

Sabbatani S, Manfredi R, Pavoni M, Consales A, Chiodo F. Voriconazole proves effective in long-term treatment of a cerebral cryptococcoma in a chronic nephropathic HIV-negative patient, after fluconazole failure. Mycopathologia. 2004;158(2):165–71.PubMedCrossRef

63.

Pitisuttithum P, Negroni R, Graybill JR, Bustamante B, Pappas P, Chapman S, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother. 2005;56(4):745–55.PubMedCrossRef

64.

Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36(9):1122–31.PubMedCrossRef

65.

Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis. 2003;37(5):728–32.PubMedCrossRef

66.

Sionov E, Chang YC, Garraffo HM, Dolan MA, Ghannoum MA, Kwon-Chung KJ. Identification of a Cryptococcus neoformans cytochrome P450 lanosterol 14alpha-demethylase (Erg11) residue critical for differential susceptibility between fluconazole/voriconazole and itraconazole/posaconazole. Antimicrob Agents Chemother. 2012;56(3):1162–9.PubMedCrossRef

67.

Loyse A, Wilson D, Meintjes G, Jarvis JN, Bicanic T, Bishop L, et al. Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis. 2012;54(1):121–8.PubMedCrossRef

68.

Bryan RA, Guimaraes AJ, Hopcraft S, Jiang Z, Bonilla K, Morgenstern A, et al. Toward developing a universal treatment for fungal disease using radioimmunotherapy targeting common fungal antigens. Mycopathologia. 2012;173(5–6):463–71

69.

Jiang Z, Bryan RA, Morgenstern A, Bruchertseifer F, Casadevall A, Dadachova E. Treatment of early and established Cryptococcus neoformans infection with radiolabeled antibodies in immunocompetent mice. Antimicrob Agents Chemother. 2012;56(1):552–4.PubMedCrossRef

70.

Bryan RA, Jiang Z, Howell RC, Morgenstern A, Bruchertseifer F, Casadevall A, et al. Radioimmunotherapy is more effective than antifungal treatment in experimental cryptococcal infection. J Infect Dis. 2010;202(4):633–7.PubMedCrossRef

71.

• Bicanic T, Brouwer A, Meintjes G, Rebe K, Limmathurotsakul D, Chierakul W, et al. Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS. 2009;23(6):701–6. This study highlights the importance of measuring and treating CSF pressure in patients with CM. PubMed

72.

Loyse A, Wainwright H, Jarvis JN, Bicanic T, Rebe K, Meintjes G, et al. Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure. AIDS. 2010;24(3):405–10.PubMedCrossRef

73.

Fessler R, Sobel J, Guyot L, Crane L, Vazquez J, Szuba M, et al. Management of elevated intracranial pressure in patients with Cryptococcal meningitis. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17(2):137–42.PubMedCrossRef

74.

Manosuthi W, Sungkanuparph S, Chottanapund S, Tansuphaswadikul S, Chimsuntorn S, Limpanadusadee P, et al. Temporary external lumbar drainage for reducing elevated intracranial pressure in HIV-infected patients with cryptococcal meningitis. Int J STD AIDS. 2008;19(4):268–71.PubMedCrossRef

75.

Park MK, Hospenthal DR, Bennett JE. Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting. Clin Infect Dis. 1999;28(3):629–33.PubMedCrossRef

76.

Newton PN, Thai le H, Tip NQ, Short JM, Chierakul W, Rajanuwong A, et al. A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin Infect Dis. 2002;35(6):769–72.PubMedCrossRef

77.

Bicanic T, Meintjes G, Rebe K, Williams A, Loyse A, Wood R, et al. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J Acquir Immune Defic Syndr. 2009;51(2):130–4.PubMedCrossRef

78.

Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(4):251–61.PubMedCrossRef

79.

Bisson G, Nthobatsong R, Thakur R, Lesetedi G, Vinekar K, Tebas P, et al. The use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitis in adults in Botswana. J Acquir Immune Defic Syndr. 2008;49(2):227–9.PubMedCrossRef

80.

Haddow L, Colebunders R, Meintjes G, Lawn S, Elliott J, Manabe Y, et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: literature review and proposed clinical case definitions. Lancet Infect Dis. 2010;10(11):791–802.PubMedCrossRef

81.

Lortholary O, Fontanet A, Memain N, Martin A, Sitbon K, Dromer F. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS. 2005;19(10):1043–9.PubMedCrossRef

82.

Sitapati A, Kao C, Cachay E, Masoumi H, Wallis R, Mathews W. Treatment of HIV-related inflammatory cerebral cryptococcoma with adalimumab. Clin Infect Dis. 2010;50(2):e7–10.PubMedCrossRef

83.

Zolopa A, Andersen J, Powderly W, Sanchez A, Sanne I, Suckow C, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One. 2009;4(5):e5575.PubMedCrossRef

84.

Makadzange AT, Ndhlovu CE, Takarinda K, Reid M, Kurangwa M, Gona P, et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin Infect Dis. 2010;50(11):1532–8.PubMedCrossRef

85.

NIH press release. May 2012. Available at: http://www.niaid.nih.gov/news/newsreleases/2012/Pages/COAT.aspx

86.

McCarthy K, Meintjes G. Guidelines for the prevention, diagnosis and management of cryptococcal meningitis and disseminated cryptococcosis in HIV-infected patients. The Southern African Journal of HIV Medicine. 2007; Spring 25–35.

87.

Chang C, Dorasamy A, Elliott J, Naranbhai V, Gosnell B, Mahabeer Y, et al. HIV+ patients with CM who attain CSF sterility pre-cART commencement experience improved outcomes in the first 24 weeks. Poster 955. 19th Conference on Retroviruses and Opportunistic Infections; 2012; Seattle, USA.

88.

Powderly W, Finkelstein D, Feinberg J, Frame P, He W, van der Horst C, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med. 1995;332(11):700–5.PubMedCrossRef

89.

Chariyalertsak S, Supparatpinyo K, Sirisanthana T, Nelson K. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis. 2002;34(2):277–84.PubMedCrossRef

90.

WHO. Essential prevention and careinterventions for adults and adolescents living with HIV in resource-limited settings. 2008.

91.

• Parkes-Ratanshi R, Wakeham K, Levin J, Namusoke D, Whitworth J, Coutinho A, et al. Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial. Lancet Infect Dis. 2011;11(12):933–41. This study shows that the risk of cryptococcal meningitis can be reduced in advanced HIV by using fluconazole prophylaxis, supporting its use in those patients for whom ART must be deferred. PubMedCrossRef

92.

Liechty C, Solberg P, Were W, Ekwaru J, Ransom R, Weidle P, et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health. 2007;12(8):929–35.PubMedCrossRef

93.

Pongsai P, Atamasirikul K, Sungkanuparph S. The role of serum cryptococcal antigen screening for the early diagnosis of cryptococcosis in HIV-infected patients with different ranges of CD4 cell counts. J Infect. 2010;60(6):474–7.PubMedCrossRef

94.

•• Jarvis J, Lawn S, Vogt M, Bangani N, Wood R, Harrison T. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis. 2009;48(7):856–62. This study suggests an approach to reduce the incidence of clinical CM in resource-limited settings by screening for CrAg in at-risk individuals. PubMedCrossRef

95.

• Meya DB, Manabe YC, Castelnuovo B, Cook BA, Elbireer AM, Kambugu A, et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis. 2010;51(4):448–55. This study shows the cost-benefit implications of a CrAg screening approach in resource-limited settings. It is shown to be a cost-effective method. PubMedCrossRef

96.

Lawn SD, Wood R. Point-of-care urine antigen screening tests for tuberculosis and cryptococcosis: potential for mortality reduction in antiretroviral treatment programs in Africa. Clin Infect Dis. 2012;54(5):739–40.PubMedCrossRef

97.

Wozniak KL, Young ML, Wormley Jr FL. Protective immunity against experimental pulmonary cryptococcosis in T cell-depleted mice. Clin Vaccine Immunol. 2011;18(5):717–23.PubMedCrossRef

Title: New Insights in the Prevention, Diagnosis, and Treatment of Cryptococcal Meningitis
Authors: Arthur Jackson
Charles van der Horst
Publication date: 01-09-2012
Publisher: Current Science Inc.
Published in: Current HIV/AIDS Reports / Issue 3/2012
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI: https://doi.org/10.1007/s11904-012-0127-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

Renal Dysfunction in the Setting of HIV/AIDS

Human Papillomavirus Vaccines: Where Do They Fit in HIV-Infected Individuals?

When to Start ART in the Setting of Acute AIDS-Related Opportunistic Infections: The Time Is Now!

Hepatitis C and HIV Co-Infection: New Drugs in Practice and in the Pipeline

The Burden of Diabetes and Hyperlipidemia in Treated HIV Infection and Approaches for Cardiometabolic Care

Osteoporosis and Bone Health in HIV

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials